Clinical Trials
296 trialsNCT07590505 2026-05-15
ULTIMO
Cancer Research Antwerp
Phase 3 Completed
NCT03979014 2026-05-06
NOVEL
Imperial College London
Phase 3 Completed
NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT05377554 2026-04-13
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT04472598 2026-03-23
TRANSFORM-1
AbbVie
Phase 3 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT05051735 2026-02-25
PARASTOP
Oslo University Hospital
Phase 3 Completed
NCT03683329 2026-02-19
DéPOH
Institut Paoli-Calmettes
Phase 3 Completed
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT05061823 2026-02-02
Bintrafusp Alfa Program Rollover Study
EMD Serono
Phase 3 Completed
NCT04442048 2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3 Completed
NCT02967289 2025-11-17
IROCAS
UNICANCER
Phase 3 Completed
NCT04534075 2025-09-08
FIDURA
Sahlgrenska University Hospital
Phase 3 Completed
NCT02330926 2025-08-29
MENAC
Norwegian University of Science and Technology
Phase 3 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04616768 2025-07-02
PROStep
Abramson Cancer Center at Penn Medicine
Phase 3 Completed
NCT01804790 2025-06-12
Néofirinox
UNICANCER
Phase 3 Completed
NCT03603184 2025-05-09
AtTEnd
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00446225 2025-03-05
EURTAC
Spanish Lung Cancer Group
Phase 3 Completed
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT03692065 2025-02-06
API-CAT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT04109066 2025-01-08
CheckMate 7FL
Bristol-Myers Squibb
Phase 3 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT03306394 2024-07-25
PRECONNECT
Servier
Phase 3 Completed
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT03506815 2024-07-05
TRIM-Line
Ottawa Hospital Research Institute
Phase 3 Completed
NCT03743051 2024-06-26
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA
Phase 3 Completed
NCT03743064 2024-06-26
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA
Phase 3 Completed
NCT03837171 2024-06-25
TRANSPORT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT02393859 2024-05-29
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT04177108 2024-03-27
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01822314 2024-03-07
ETNA
Fondazione Michelangelo
Phase 3 Completed
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04303013 2023-11-01
Guided Meditation During Radiotherapy.
Mayo Clinic
Phase 3 Completed
NCT04534725 2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT00106691 2023-06-12
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
GTx
Phase 3 Completed
NCT00674609 2023-05-03
SPRAY
Jazz Pharmaceuticals
Phase 3 Completed